XFOR - X4 Pharmaceuticals, Inc
3.22
-0.080 -2.484%
Share volume: 166,101
Last Updated: 05-06-2025
Pharmaceutical Products/Biological Products, Except Diagnostic Substances:
-0.08%
PREVIOUS CLOSE
CHG
CHG%
$3.30
-0.08
-0.02%
View ratios
| Fiscal Date | 03-31-2024 | 06-30-2024 | 09-30-2024 | 12-31-2024 | 03-31-2025 | |
|---|---|---|---|---|---|---|
| Fiscal Quarter | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | |
| Report Date | 05-07-2024 | 08-08-2024 | 11-13-2024 | 03-25-2025 | 05-01-2025 | |
| Total revenue | 0.000 | 563.000 K | 560.000 K | 1.434 M | 28.807 M | |
| Cost of revenue | 0.000 | 268.000 K | 227.000 K | 302.000 K | 4.716 M | |
| Gross profit | 0.000 | 295.000 K | 333.000 K | 1.132 M | 24.091 M | |
| inf% | 12.88% | 239.94% | 2,028.18% | |||
| Operating expenses | 37.289 M | 34.192 M | 34.833 M | 36.847 M | 33.534 M | |
| Selling general and admin | 17.435 M | 13.278 M | 15.660 M | 15.145 M | 15.021 M | |
| Research and development | 19.854 M | 20.914 M | 19.173 M | 21.702 M | 18.513 M | |
| Total expenses | 37.289 M | -70.808 M | 34.833 M | 36.847 M | 33.534 M | |
| -289.89% | 149.19% | 5.78% | -8.99% | |||
| Operating income | -37.289 M | 71.103 M | -34.500 M | -35.715 M | -9.443 M | |
| Ebit | -50.939 M | 91.462 M | -36.138 M | -38.526 M | 1.492 M | |
| Pretax income | -51.747 M | 90.851 M | -36.681 M | -39.563 M | 316.000 K | |
| -275.57% | -140.37% | 7.86% | -100.80% | |||
| Income tax | 19.000 K | 18.000 K | 15.000 K | 258.000 K | 34.000 K | |
| Net income basic | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Net income | -51.766 M | 90.833 M | -36.696 M | -39.821 M | 282.000 K | |
| 275.47% | -140.40% | -8.52% | 100.71% |
